

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A substantially pure polypeptide complex comprising a Clostridium botulinum neurotoxin and more than one Clostridium botulinum type E neurotoxin associate polypeptide.
- 2-6. (Canceled)
7. (Withdrawn) A substantially pure Clostridium botulinum serotype E neurotoxin associated polypeptide.
- 8-16. (Canceled)
17. (Withdrawn) A substantially pure antibody that specifically binds to a Clostridium botulinum type E neurotoxin associated polypeptide having a molecular weight of approximately 80, 60, 45, or 18 kDa, or to a complex of any two or more of said neurotoxin associated polypeptides.
18. (Withdrawn) A substantially pure antibody that specifically binds to a polypeptide complex of claim 1.
19. (Withdrawn) A method of detecting a serotype E neurotoxin complex in a sample, the method comprising:
 - (a) contacting the sample with an antibody of claim 17, and

(b) detecting antibody-bound polypeptide, if any, in the sample, the presence of antibody-bound polypeptide indicating the presence of serotype E neurotoxin in the sample.

20. (Withdrawn) The method of claim 19, wherein the sample is a foodstuff.
21. (Withdrawn) The method of claim 19, wherein the sample is a gastrointestinal, blood, or tissue sample obtained from a vertebrate animal.
22. (Currently amended) A method of treating a patient who is suffering from a disease or condition associated with exaggerated release of acetylcholine from presynaptic nerve terminals, the method comprising administering to the patient ~~a therapeutically effective amount of a~~ composition comprising a substantially pure polypeptide complex comprising a Clostridium botulinum neurotoxin and one or more Clostridium botulinum type E neurotoxin associated ~~polypeptide~~ polypeptides selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, a polypeptide comprising the amino acid sequence of SEQ ID NO:3, a polypeptide comprising the amino acid sequence of SEQ ID NO:2, a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and a polypeptide comprising the amino acid sequence of SEQ ID NO:5 in an amount sufficient to reduce acetylcholine release from presynaptic nerve terminals.
23. (Currently amended) The method of claim 22, wherein the ~~excessive~~ exaggerated acetylcholine release causes undesirable contraction of smooth or skeletal muscle cells.
24. (Currently amended) The method of claim 22, wherein the ~~excessive~~ exaggerated release of acetylcholine causes profuse sweating, lacrimation, or mucous secretion.
25. (Withdrawn) A method of treating a patient who is suffering from spasticity occurring secondary to brain ischemia, or traumatic injury of the brain or spinal cord, the method comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.

26. (Withdrawn) A method of treating a patient who is suffering from tension headache or pain, the method comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.

27-29. (Canceled)

30. (Withdrawn) A method of detecting a Clostridium botulinum serotype E neurotoxin in a sample, the method comprising:

- (a) contacting the sample with a Clostridium botulinum type E neurotoxin associated polypeptide (NAP) of claim 7 that specifically binds a serotype E botulinum neurotoxin and thereby forms a NAP-neurotoxin complex, and
- (b) detecting the NAP-neurotoxin complex, if any, in the sample, the presence of a complex indicating the presence of serotype E neurotoxin in the sample.

31-32. (Canceled)

33. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:4.

34. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:3.

35. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:2.

36. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:1.

37. (Previously presented) The method of claim 25, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:5.